Evidence map›Paper›PMID 37231231›Full record

ArticleJournal of neuro-oncology2023

A novel prognostic model based on pretreatment serum albumin and ECOG PS for primary CNS lymphoma: an international, multi-center study.

Li Wei, Yuting Gao, Katharina Theresa Prochazka, Rongqiu Liu, Liang Wang, Boyang Liu, Yingzhi He, Luca Bertero, Alessia Pellerino, Paola Cassoni and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. The Role of Platelet to Lymphocyte Ratio (PLR) in Predicting Early Treatment Response in Diffuse Large B Cell Lymphoma.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 4 countries.

Li Wei *NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Population and Family Planning Science and Technology Research Institute, Chongqing, China.
Yuting Gao *Laboratory for Excellence in Systems Biomedicine of Pediatric Oncology, Department of Pediatric Hematology and Oncology, Children's Hospital of Chongqing Medical University, 136 Zhongshan Second Rd., Yuzhong District, Chongqing, 401122, China.
Katharina Theresa Prochazka *Clinical Department of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8010, Graz, Austria.
Rongqiu LiuLaboratory for Excellence in Systems Biomedicine of Pediatric Oncology, Department of Pediatric Hematology and Oncology, Children's Hospital of Chongqing Medical University, 136 Zhongshan Second Rd., Yuzhong District, Chongqing, 401122, China.
Liang WangDepartment of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Boyang LiuDepartment of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China On Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory On Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Yingzhi HeDepartment of Hematology, ZhuJiang Hospital of Southern Medical University, Guangzhou, China.
Luca BerteroPathology Unit, Department of Medical Sciences, University of Turin, Via Santena 7, 10126, Turin, Italy.
Alessia PellerinoDepartment of Neuro-Oncology, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Turin, Italy.
Paola CassoniPathology Unit, Department of Medical Sciences, University of Turin, Via Santena 7, 10126, Turin, Italy.
Luca TamagnoneDepartment of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 10068, Rome, Italy.
Alexander J DeutschClinical Department of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8010, Graz, Austria.
Huien ZhanDepartment of Hematology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Jing LaiDepartment of Hematology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Seok Jin KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. kstwoh@skku.edu.
Hua YouLaboratory for Excellence in Systems Biomedicine of Pediatric Oncology, Department of Pediatric Hematology and Oncology, Children's Hospital of Chongqing Medical University, 136 Zhongshan Second Rd., Yuzhong District, Chongqing, 401122, China. youhua307@163.com.
China International Science and Technology Cooperation · CNFirst Affiliated Hospital of Jinan University · CNMedical University of Graz · ATSouthern Medical University · CNUniversity of Turin · ITAgostino Gemelli University Polyclinic · ITBeijing Tongren Hospital · CNChildren's Hospital of Chongqing Medical University · CNFirst People's Hospital of Chongqing · CNPiedmont Reference Center for Epidemiology and Cancer Prevention · ITSungkyunkwan University · KR

Funding

Chongqing Science and Technology Bureau CSTB2022NSCQ-MSX0227CQMU Program for Youth Innovation in Future Medicine W0202
6 · The paper itself

Abstract

backgroundSerum albumin has been demonstrated as prognostic parameter in non-Hodgkin lymphoma (NHL). Primary central nervous system lymphoma (PCNSL) is a rare extranodal NHL with highly aggressive behavior. In this study, we aimed at creating a novel prognostic model for PCNSL based on serum albumin levels.

methodsWe compared several commonly used laboratory nutritional parameters for predicting the survival of PCNSL patients using overall survival (OS) for outcome analysis and receiver operating characteristic curve analysis to determine the optimal cut-off values. Parameters associated with OS were evaluated by univariate and multivariate analyses. Independent prognostic parameters for OS were selected for risk stratification, including albumin ≤ 4.1 g/dL, ECOG PS > 1, and LLR > 166.8, which were associated with shorter OS; albumin > 4.1 g/dL, ECOG PS 0-1 and LLR ≤ 166.8, which were associated with longer OS, and five-fold cross-validation was used for evaluating predictive accuracy of identified prognostic model.

resultsBy univariate analysis, age, ECOG PS, MSKCC score, Lactate dehydrogenase-to-lymphocyte ratio (LLR), total protein, albumin, hemoglobin, and albumin to globulin ratio (AGR) resulted statistically associated with the OS of PCNSL. By multivariate analysis, albumin ≤ 4.1 g/dL, ECOG PS > 1, and LLR > 166.8 were confirmed to be significant predictors of inferior OS. We explored several PCNSL prognostic models based on albumin, ECOG PS and LLR with 1 point assigned to each parameter. Eventually, a novel and effective PCNSL prognostic model based on albumin and ECOG PS successfully classified patients into three risk groups with 5-year survival rates of 47.5%, 36.9%, and 11.9%, respectively.

conclusionsThe novel two-factor prognostic model based on albumin and ECOG PS we propose represents a simple but significant prognostic tool for assessing newly diagnosed patients with PCNSL.

Indexed as

Lymphoma, Non-HodgkinSerum AlbuminHumansLymphocytesPrognosisRetrospective StudiesSerum AlbuminAlbuminEastern Cooperative Oncology Group performance status (ECOG PS)Multi-center studyPrimary central nervous system lymphomaPrognostic model

Identifiers

PMID37231231
OpenAlexW4378349568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.